The first approval of a gene therapy for congenital disease in the US (Luxturna) inaugurates a new – though long anticipated – era for therapeutics. Along with questions around durability of response …
During the UnitedHealth quarterly earnings call earlier this month, Larry Renfro, CEO of Optum, offered some additional color on the growth of OptumCare: “Combined with [Davita], OptumCare will be in …
Playing chess against cancer
Tumors are not intelligent, but, because they have escaped mutational control, they constantly probe for mutations that will allow them to escape chemotherapeutic suppress…
(For background on Pennsylvania market, please take a look at previous note here)
Summary
The UPMC/Highmark rivalry continues to open new fronts in Pennsylvania
Highmark’s response to UPMC is differe…
(For Louisiana market context, please take a look at previous notes on Ochsner here and here)
Before the holidays, Ochsner signed an LOI to take over the management of ailing University Health located…
Successes in gene therapy for hemophilia B and A
Hemophilia A and B are X-linked genetic diseases which prevents the formation of functional coagulant factors VII and IX respectively and cause a prope…
This website collects cookies to deliver better user experience and to analyze our website traffic and performance; we never collect any personal data or target you with ads.
